NEUROFIBROMA, PLEXIFORM
Clinical trials for NEUROFIBROMA, PLEXIFORM explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMA, PLEXIFORM trials appear
Sign up with your email to follow new studies for NEUROFIBROMA, PLEXIFORM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for NF1 patients: targeted drug shrinks inoperable tumors in early trial
Disease control OngoingThis early-stage study tests the safety and effectiveness of selumetinib, a drug that blocks a key cancer growth signal, in 32 Chinese children and adults with neurofibromatosis type 1 (NF1) who have inoperable plexiform neurofibromas (nerve tumors). Participants take the drug by…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 11:02 UTC
-
Promising drug may shrink inoperable tumors in kids with rare genetic condition
Disease control OngoingThis study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink the tumors or stop them from growing. Participants take the d…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 10:33 UTC
-
New hope for kids with rare tumor disorder: drug shows promise in Real-World study
Disease control OngoingThis study looks at how safe and effective the drug selumetinib is for children aged 3 to 16 with a condition called neurofibromatosis type 1 (NF1) that causes painful, non-cancerous tumors that cannot be removed by surgery. About 80 to 100 children in China will take the drug an…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Sponsor: AstraZeneca • Aim: Disease control
Last updated May 22, 2026 14:01 UTC